Wednesday, December 12, 2018
Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseases
Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area for Almirall. X-Chem, Inc. is a privately held biotechnology company focused on applying its industry…
Read full story
- Paratek Pharmaceuticals, Inc.
Thursday, August 09, 2018
The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (…Read the full story